Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men | Zendy

Spyridon P. Basourakos | Zendy; Roman Gulati | Zendy; Randy Vince | Zendy; Daniel E. Spratt | Zendy; Patrick Lewicki | Zendy; Alexander J. Hill | Zendy; Yaw A. Nyame | Zendy; Jennifer Cullen | Zendy; Sarah C. Markt | Zendy; Christopher E. Barbieri | Zendy; Jim C. Hu | Zendy; Erika S. Trapl | Zendy; Jonathan E. Shoag | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men

Author(s) -

Spyridon P. Basourakos,

Roman Gulati,

Randy Vince,

Daniel E. Spratt,

Patrick Lewicki,

Alexander J. Hill,

Yaw A. Nyame,

Jennifer Cullen,

Sarah C. Markt,

Christopher E. Barbieri,

Jim C. Hu,

Erika S. Trapl,

Jonathan E. Shoag

Publication year - 2022

Publication title -

nejm evidence

Language(s) - English

Resource type - Journals

ISSN - 2766-5526

DOI - 10.1056/evidoa2200031

Subject(s) - overdiagnosis , medicine , prostate cancer , prostate cancer screening , epidemiology , incidence (geometry) , population , demography , relative risk , cancer , prostate , gynecology , prostate specific antigen , confidence interval , environmental health , physics , sociology , optics

Prostate-specific antigen screening has profoundly affected the epidemiology of prostate cancer in the United States. Persistent racial disparities in outcomes for Black men warrant re-examination of the harms of screening relative to its cancer-specific mortality benefits in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research